Summary

Join us for a timely and informative webinar on HER2-Low and Ultralow Metastatic Breast Cancer: Evolving Definitions, Emerging Evidence, and Shifting Treatment Paradigms, featuring internationally recognized breast medical oncologist Dr. Neil Iyengar, who will share the latest insights and clinical trial data shaping global practice. Providing the Canadian perspective is Dr. Nicholas Meti, a respected clinician in the breast cancer field, who will moderate the session and highlight how these advances are being applied in Canadian care settings. Don't miss this opportunity to gain expert guidance on navigating the evolving landscape of HER2-low and ultralow disease.


This activity has been funded by an educational grant from AstraZeneca and Daiichi Sankyo and is intended for healthcare practitioners only.

Highlights

  • 1

    To provide an update on recent clinical trial results involving patients with HER2-low and HER2-ultralow metastatic breast cancer, highlighting key findings from both global and Canadian research efforts.

  • 2

    To put into clinical perspective advances in the treatment of these subtypes and the evolving treatment paradigm, with a focus on applicability in Canadian clinical practice alongside international trends.

  • 3

    To provide an overview of definitions of HER2-low, HER2-ultralow, and HER2-negative metastatic breast cancer, incorporating both international and Canadian classifications and diagnostic considerations.

User

Dr. Nicholas Meti

Program Director, Medical Oncology Residency Training Program, McGill University

User

Dr. Neil Iyengar

Co-Director, Breast Medical Oncology, Winship Cancer Institute at Emory University

Comments (0)